These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
    Author: Chiu S, Paulose CS, Mishra RK.
    Journal: Peptides; 1981; 2(1):105-11. PubMed ID: 6113579.
    Abstract:
    The mechanism of action subserving the potential anti-Parkinsonian properties of L-prolyl-L-leucyl-glycinamide (PLG) was investigated in behavioural and neurochemical models of dopaminergic function in the rat. Acute administration of PLG (20 and 40 mg kg-1 SC) failed to alter appreciably the intensity of the cataleptic response elicited by haloperidol (3 mg kg-1 IP). By contrast, chronic PLG treatment (20, 40 and 80 mg kg-1 SC twice daily for five days) significantly attenuated haloperidol-induced catalepsy. The effect of PLG on in vitro dopamine/neuroleptic receptor binding in rat striatum as differentially labelled by apomorphine and spiroperidol was also examined. PLG selectively enhanced the affinity of the specific binding of agonist [3H] apomorphine to dopamine receptors in the striatum, but had no effect on [3H] spiroperidol binding. The behavioural and biochemical results obtained in the present study raise the possibility that PLG may facilitate nigro-striatal dopaminergic neurotransmission through interacting with a unique PLG receptor functionally coupled to the dopamine receptor-adenylate cyclase complex.
    [Abstract] [Full Text] [Related] [New Search]